<i>Mφ-c-Myc-KO</i> mice are resistant to growth of tumors derived from injected B16 melanoma cells.

<p>(<b>A</b>) B16 melanoma cells expressing firefly luciferase were injected subcutaneously into both flanks of mice, and tumor growth was monitored over two weeks post-grafting with the Xenogen IVIS 100 Bioluminescence <i>in vivo</i> imaging system (n = 6–8 tumors per genotype). (<b>B</b>) Tumor volume after sacrifice at two weeks post-injection (n = 16 tumors per genotype). (<b>C</b>) Flow cytometry analysis for circulating CD11b⁺ myeloid cells, CD4⁺ T lymphocytes, CD8⁺ T lymphocytes and CD19⁺ B lymphocytes in mice two weeks after tumor injection (n = 7, control; n = 8 <i>Mφ-c-Myc-KO</i>). (<b>D</b>) Flow cytometry detection of circulating myeloid cells two weeks after tumor injection (n = 7, control; n = 8, <i>Mφ-c-MYC-KO</i>) (<b>E</b>) Representative confocal images showing double immunofluorescence to visualize macrophages (CD68⁺ cells) and c-MYC expression in tumors, and quantification of <i>c-Myc</i> mRNA in TAMs isolated by sorting tumor cell suspensions (n = 3 mice per genotype; two tumors pooled per mouse). (<b>F</b>) Representative confocal images and quantification of proliferating TAMs (CD68+Ki67+) (n = 6 tumors per genotype). (<b>G</b>) Representative confocal images and quantification of apoptotic TAMs (CD68+TUNEL+) (n = 6 tumors per genotype).